Welcome to our dedicated page for Co-Diagnostics news (Ticker: CODX), a resource for investors and traders seeking the latest updates and insights on Co-Diagnostics stock.
Co-Diagnostics, Inc. reports developments in molecular diagnostics, including its patented platform for designing molecular diagnostic tests and its Co-Dx PCR platform. Company news commonly covers clinical and regulatory disclosures, commercialization activity through CoSara and CoMira joint ventures, intellectual property and technology updates, and operating and financial results.
Recurring updates also include material agreements, governance matters, capital-structure actions, and securities-listing developments. The company’s public disclosures connect its diagnostic-test pipeline, platform development, and commercialization strategy with financing, shareholder approvals, and other corporate actions.
Co-Diagnostics, Inc. (Nasdaq: CODX) will showcase its diagnostics products at the AACC Annual Scientific Meeting & Clinical Lab Expo from July 24-28 in Chicago, IL. The Company invites distributors and customers for a global update on July 26 at 11 am CT in room S103A. CEO Dwight Egan will present on the Co-Dx PCR Home testing platform at 2 pm CT on July 26. Co-Dx has sold over 34 million PCR tests across more than 50 countries. The Co-Dx PCR Home testing platform is under FDA review and not yet available for sale.
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) announced the shipment of testing reagents for monkeypox virus to an international distributor amidst a global outbreak. As of July 7, 2022, over 6,000 monkeypox cases have been reported across 59 countries, according to the World Health Organization. The reagents were developed quickly to meet urgent regional demands. CEO Dwight Egan emphasized the importance of their PCR-based testing products for effective disease detection, underscoring the company's commitment to high-quality, affordable diagnostics worldwide.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced its presentation at the 29th International Biodetection Technologies Conference, held virtually on June 28-29, 2022. CEO Dwight Egan will discuss the upcoming PCR Home testing platform during the Point-of-Care Diagnostics agenda on June 29 at 12:30 pm ET. This conference focuses on the latest innovations in the detection and identification of biological threats. An archived version of the presentation will be available on the company's website post-conference.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced that key executives will participate in the Sidoti Summer Small Cap Virtual Investor Conference on June 15-16, 2022. CEO Dwight Egan, CFO Brian Brown, and Head of Investor Relations Andrew Benson will present and hold one-on-one meetings with investors. The presentation starts at 3:15 p.m. EDT on June 15 and can be accessed via the company's website. Co-Diagnostics specializes in molecular diagnostics, focusing on developing tests that analyze nucleic acid molecules for various applications, including infectious diseases.
Co-Diagnostics, Inc. (Nasdaq: CODX) is participating in the 22nd MEDEXPO Africa 2022 in Nairobi, Kenya from June 9-11. This significant event showcases over 30 countries' medical technology solutions, aiming at buyers seeking innovative products and services. This marks Co-Dx's first trade show in Africa, enhancing its initiative to promote COVID-19 and other infectious disease tests across the continent. Notably, the company has completed the design of a PCR test for monkeypox. Interested attendees can find Co-Dx at Booth #124.
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) has completed the principal design of a PCR test for the monkeypox virus, amid a multi-country outbreak. The test will leverage the Company's patented CoPrimer™ technology and proprietary software system. CEO Dwight Egan emphasized the need for prompt action against potential outbreaks, highlighting Co-Dx's mission to enhance access to affordable, high-quality molecular testing globally. The World Health Organization reported monkeypox cases in 18 non-endemic countries since May 13, 2022.
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) announced its participation at the H.C. Wainwright & Co. 2022 Global Investment Conference, scheduled for May 23-26 in Miami, Florida. CEO Dwight Egan will present on May 25 at 1:30 PM ET, discussing the company's recent performance and its new Co-Dx PCR Home Diagnostic Platform. Egan highlighted Florida's significance as a market, contributing over $28 million in revenue since the pandemic began. The conference aims to engage institutional investors and industry professionals.
Co-Diagnostics, Inc. (NASDAQ: CODX) reported record first-quarter revenue of $22.7 million and a diluted EPS of $0.34 for the period ending March 31, 2022. Revenue growth was driven mainly by sales of the Logix Smart™ COVID-19 Test. Gross profit rose to $19.4 million, reflecting an 85.5% gross margin. However, operating income slightly decreased to $9.8 million due to increased R&D expenses. Cash reserves increased to $97.4 million, providing a strong foundation for future growth. Despite positive results, management highlighted challenges in forecasting future COVID-19 test sales due to changing market conditions.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced its participation at the Medical Fair Brasil from May 3-6, 2022, in São Paulo. This international exhibition focuses on hospital and diagnostic supplies, attracting key healthcare professionals. Co-Dx will showcase its innovative molecular diagnostic technologies, including a new point-of-care rapid PCR diagnostics platform. The event offers an opportunity for Company representatives to connect directly with decision-makers in healthcare, enhancing product visibility and potential sales.
Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company, announced that it will release its first quarter 2022 financial results on May 12, 2022, after market close. A conference call and webcast will follow at 4:30 p.m. EDT to discuss these results with analysts and investors. Key management, including CEO Dwight Egan and CFO Brian Brown, will participate in the call. The call will be accessible via the company's website and will also be recorded for later viewing.